1
|
Figueres L, Bruneau S, Prot-Bertoye C, Brideau G, Néel M, Griveau C, Cheval L, Bignon Y, Dimitrov J, Dejoie T, Ville S, Kandel-Aznar C, Moreau A, Houillier P, Fakhouri F. Hypomagnesemia, Hypocalcemia, and Tubulointerstitial Nephropathy Caused by Claudin-16 Autoantibodies. J Am Soc Nephrol 2022; 33:1402-1410. [PMID: 35728884 PMCID: PMC9257800 DOI: 10.1681/asn.2022010060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 03/22/2022] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Chronic hypomagnesemia is commonly due to diarrhea, alcoholism, and drugs. More rarely, it is caused by genetic defects in the effectors of renal magnesium reabsorption. METHODS In an adult patient with acquired severe hypomagnesemia, hypocalcemia, tubulointerstitial nephropathy, and rapidly progressing kidney injury, similarities between the patient's presentation and features of genetic disorders of renal magnesium transport prompted us to investigate whether the patient had an acquired autoimmune cause of renal magnesium wasting. To determine if the patient's condition might be explained by autoantibodies directed against claudin-16 or claudin-19, transmembrane paracellular proteins involved in renal magnesium absorption, we conducted experiments with claudin knockout mice and transfected mouse kidney cells expressing human claudin-16 or claudin-19. We also examined effects on renal magnesium handling in rats given intravenous injections of IgG purified from sera from the patient or controls. RESULTS Experiments with the knockout mice and in vitro transfected cells demonstrated that hypomagnesemia in the patient was causally linked to autoantibodies directed against claudin-16, which controls paracellular magnesium reabsorption in the thick ascending limb of Henle's loop. Intravenous injection of IgG purified from the patient's serum induced a marked urinary waste of magnesium in rats. Immunosuppressive treatment combining plasma exchange and rituximab was associated with improvement in the patient's GFR, but hypomagnesemia persisted. The patient was subsequently diagnosed with a renal carcinoma that expressed a high level of claudin-16 mRNA. CONCLUSIONS Pathogenic claudin-16 autoantibodies represent a novel autoimmune cause of specific renal tubular transport disturbances and tubulointerstitial nephropathy. Screening for autoantibodies targeting claudin-16, and potentially other magnesium transporters or channels in the kidney, may be warranted in patients with acquired unexplained hypomagnesemia.
Collapse
Affiliation(s)
- Lucile Figueres
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
| | - Sarah Bruneau
- Centre de Recherche en Transplantation et Immunologie, Nantes, France.,Institut de Transplantation Urologie Néphrologie, Nantes, France
| | - Caroline Prot-Bertoye
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.,Department of Physiology, Hôpital Européen Georges Pompidou, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte, Paris, France.,CNRS, Paris, France
| | - Gaëlle Brideau
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.,CNRS, Paris, France
| | - Mélanie Néel
- Centre de Recherche en Transplantation et Immunologie, Nantes, France.,Institut de Transplantation Urologie Néphrologie, Nantes, France
| | - Camille Griveau
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.,CNRS, Paris, France
| | - Lydie Cheval
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.,CNRS, Paris, France
| | - Yohan Bignon
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.,CNRS, Paris, France
| | - Jordan Dimitrov
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France
| | - Thomas Dejoie
- Laboratory of Biochemistry, CHU de Nantes, Nantes, France
| | - Simon Ville
- Centre de Recherche en Transplantation et Immunologie, Nantes, France.,Institut de Transplantation Urologie Néphrologie, Nantes, France.,Department of Nephrology, CHU de Nantes, Nantes, France
| | | | - Anne Moreau
- Department of Pathology, CHU de Nantes, Nantes, France
| | - Pascal Houillier
- Centre de recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France .,Department of Physiology, Hôpital Européen Georges Pompidou, Paris, France.,Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte, Paris, France.,CNRS, Paris, France
| | - Fadi Fakhouri
- Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland
| |
Collapse
|
2
|
Dehmani S, Nerrière-Daguin V, Néel M, Elain-Duret N, Heslan JM, Belarif L, Mary C, Thepenier V, Biteau K, Poirier N, Blancho G, Haspot F. SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation. Front Immunol 2021; 12:732530. [PMID: 34925315 PMCID: PMC8671138 DOI: 10.3389/fimmu.2021.732530] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 10/05/2021] [Indexed: 11/16/2022] Open
Abstract
A numerous number of positive and negative signals via various molecules modulate T-cell activation. Within the various transmembrane proteins, SIRPγ is of interest since it is not expressed in rodents. SIRPγ interaction with CD47 is reevaluated in this study. Indeed, we show that the anti-SIRPγ mAb clone LSB2.20 previously used by others has not been appropriately characterized. We reveal that the anti-SIRPα clone KWAR23 is a Pan anti-SIRP mAb which efficiently blocks SIRPα and SIRPγ interactions with CD47. We show that SIRPγ expression on T cells varies with their differentiation and while being expressed on Tregs, is not implicated in their suppressive functions. SIRPγ spatial reorganization at the immune synapse is independent of its interaction with CD47. In vitro SIRPα-γ/CD47 blockade with KWAR23 impairs IFN-γ secretion by chronically activated T cells. In vivo in a xeno-GvHD model in NSG mice, the SIRPγ/CD47 blockade with the KWAR23 significantly delays the onset of the xeno-GvHD and deeply impairs human chimerism. In conclusion, we have shown that T-cell interaction with CD47 is of importance notably in chronic stimulation.
Collapse
Affiliation(s)
- Safa Dehmani
- OSE Immunotherapeutics, Nantes, France.,Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Véronique Nerrière-Daguin
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Mélanie Néel
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Nathan Elain-Duret
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Jean-Marie Heslan
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | | | | | | | | | | | - Gilles Blancho
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Fabienne Haspot
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| |
Collapse
|
3
|
Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, Pengam S, Teppaz G, Thepenier V, Danger R, Robert-Siegwald G, Néel M, Bruneau S, Glémain A, Néel A, Poupon A, Mosnier JF, Chêne G, Dubourdeau M, Blancho G, Vanhove B, Poirier N. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Sci Adv 2021; 7:eabd1453. [PMID: 33811066 PMCID: PMC11057782 DOI: 10.1126/sciadv.abd1453] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 02/16/2021] [Indexed: 06/12/2023]
Abstract
Resolution of inflammation is elicited by proresolving lipids, which activate GPCRs to induce neutrophil apoptosis, reduce neutrophil tissue recruitment, and promote macrophage efferocytosis. Transcriptional analyses in up to 300 patients with Inflammatory Bowel Disease (IBD) identified potential therapeutic targets mediating chronic inflammation. We found that ChemR23, a GPCR targeted by resolvin E1, is overexpressed in inflamed colon tissues of severe IBD patients unresponsive to anti-TNFα or anti-α4β7 therapies and associated with significant mucosal neutrophil accumulation. We also identified an anti-ChemR23 agonist antibody that induces receptor signaling, promotes macrophage efferocytosis, and reduces neutrophil apoptosis at the site of inflammation. This ChemR23 mAb accelerated acute inflammation resolution and triggered resolution in ongoing chronic colitis models, with a significant decrease in tissue lesions, fibrosis and inflammation-driven tumors. Our findings suggest that failure of current IBD therapies may be associated with neutrophil infiltration and that ChemR23 is a promising therapeutic target for chronic inflammation.
Collapse
Affiliation(s)
- C Trilleaud
- OSE Immunotherapeutics, Nantes, France
- Université de Nantes
| | | | - K Biteau
- OSE Immunotherapeutics, Nantes, France
| | - I Girault
- OSE Immunotherapeutics, Nantes, France
| | - L Belarif
- OSE Immunotherapeutics, Nantes, France
| | - C Mary
- OSE Immunotherapeutics, Nantes, France
| | - S Pengam
- OSE Immunotherapeutics, Nantes, France
| | - G Teppaz
- OSE Immunotherapeutics, Nantes, France
| | | | - R Danger
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | | | - M Néel
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | - S Bruneau
- Université de Nantes
- [ITUN], 44000 Nantes, France
| | - A Glémain
- Université de Nantes
- [ITUN], 44000 Nantes, France
| | - A Néel
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- Service de Médecine Interne, CHU de Nantes, Nantes, France
| | | | - J F Mosnier
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes, France
| | - G Chêne
- Ambiotis, Canal Biotech 2, Toulouse, France
| | | | - G Blancho
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | - B Vanhove
- OSE Immunotherapeutics, Nantes, France
| | - N Poirier
- OSE Immunotherapeutics, Nantes, France.
| |
Collapse
|
4
|
Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest 2021; 130:6109-6123. [PMID: 33074246 DOI: 10.1172/jci135528] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 08/06/2020] [Indexed: 12/12/2022] Open
Abstract
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed in preclinical models, the therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, in humans remains unknown. We report a potent synergy between selective SIRPα blockade and ICB in increasing memory T cell responses and reverting exclusion in syngeneic and orthotopic tumor models. Selective SIRPα blockade stimulated tumor nest T cell recruitment by restoring murine and human macrophage chemokine secretion and increased anti-tumor T cell responses by promoting tumor-antigen crosspresentation by dendritic cells. However, nonselective SIRPα/SIRPγ blockade targeting CD47 impaired human T cell activation, proliferation, and endothelial transmigration. Selective SIRPα inhibition opens an attractive avenue to overcoming ICB resistance in patients with elevated myeloid cell infiltration in solid tumors.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Mélanie Néel
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Georgia Porto
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | | - Richard Danger
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Nicolas Vince
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | | - Riad Abes
- OSE Immunotherapeutics, Nantes, France
| | | | - Charlène Trilleaud
- OSE Immunotherapeutics, Nantes, France.,Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Kerry Ralph
- Cancer Immunology & Immune Modulation, Boehringer Ingelheim, Ridgefield, Connecticut, USA
| | - E Sergio Trombetta
- Cancer Immunology & Immune Modulation, Boehringer Ingelheim, Ridgefield, Connecticut, USA
| | - Alexandra Garcia
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Virginie Vignard
- CHU Nantes, Nantes, France.,Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - Bernard Martinet
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Alexandre Glémain
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Sarah Bruneau
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Fabienne Haspot
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Safa Dehmani
- OSE Immunotherapeutics, Nantes, France.,Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Pierre Duplouye
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Masayuki Miyasaka
- Immunology Frontier Research Center, Osaka University, Yamada-oka, Suita, Japan
| | - Nathalie Labarrière
- Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - David Laplaud
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Stéphanie Le Bas-Bernardet
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Christophe Blanquart
- Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - Véronique Catros
- Université de Rennes, INSERM, CHU Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR_S 1241, CRB Santé Rennes, Rennes, France
| | - Pierre-Antoine Gouraud
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Isabelle Archambeaud
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive
| | - Hélène Aublé
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive.,Centre d'investigation Clinique and
| | - Sylvie Metairie
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive
| | - Jean-François Mosnier
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes, France
| | | | - Gilles Blancho
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Sophie Conchon
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | |
Collapse
|
5
|
Néel A, Bucchia M, Néel M, Tilly G, Caristan A, Yap M, Rimbert M, Bruneau S, Cadoux M, Agard C, Hourmant M, Godmer P, Brouard S, Bressollette C, Hamidou M, Josien R, Fakhouri F, Degauque N. Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2019; 71:641-650. [PMID: 30375745 DOI: 10.1002/art.40766] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 10/25/2018] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To compare the effects of rituximab (RTX) and conventional immunosuppressants (CIs) on CD4+ T cells, Treg cells, and CD8+ T cells in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS A thorough immunophenotype analysis of CD4+, Treg, and CD8+ cells from 51 patients with AAV was performed. The production of cytokines and chemokines by CD8+ T cells stimulated in vitro was assessed using a multiplex immunoassay. The impact of AAV B cells on CD8+ T cell response was assessed using autologous and heterologous cocultures. RESULTS CD4+ and Treg cell subsets were comparable among RTX-treated and CI-treated patients. In contrast, within the CD8+ T cell compartment, RTX, but not CIS, reduced CD45RA+CCR7- (TEMRA) cell frequency (from a median of 39% before RTX treatment to 10% after RTX treatment [P < 0.01]) and efficiently dampened cytokine/chemokine production (e.g., the median macrophage inflammatory protein 1α level was 815 pg/ml in patients treated with RTX versus 985 pg/ml in patients treated with CIs versus 970 pg/ml in those with active untreated AAV [P < 0.01]). CD8+ T cell subsets cocultured with autologous B cells produced more proinflammatory cytokines in AAV patients than in controls (e.g., for tumor necrosis factor-producing effector memory CD8+ T cells: 14% in AAV patients versus 9.2% in controls [P < 0.05]). In vitro disruption of AAV B cell-CD8+ T cell cross-talk reduced CD8+ T cell cytokine production, mirroring the reduced CD8+ response observed ex vivo after RTX treatment. CONCLUSION The disruption of a pathogenic B cell/CD8+ T cell axis may contribute to the efficacy of RTX in AAV. Further studies are needed to determine the value of CD8+ T cell immunomonitoring in B cell-targeted therapies.
Collapse
Affiliation(s)
- Antoine Néel
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Marie Bucchia
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Mélanie Néel
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Gaelle Tilly
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Aurélie Caristan
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | | | - Marie Rimbert
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Sarah Bruneau
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Marion Cadoux
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | | | - Maryvonne Hourmant
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes France, and Centre Hospitalier Bretagne Atlantique, Vannes, France
| | - Pascal Godmer
- Centre Hospitalier Bretagne Atlantique, Vannes, France
| | - Sophie Brouard
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | | | - Mohamed Hamidou
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Regis Josien
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Fadi Fakhouri
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| | - Nicolas Degauque
- INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France
| |
Collapse
|
6
|
Laurent L, Le Fur A, Le Bloas R, Néel M, Mary C, Moreau A, Poirier N, Vanhove B, Fakhouri F. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28. Eur J Immunol 2017. [DOI: 10.1002/eji.201746923] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Laetitia Laurent
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Awena Le Fur
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- Department of nephrology and immunology; Centre Hospitalier Universitaire; Nantes France
| | - Rozenn Le Bloas
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Mélanie Néel
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Caroline Mary
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Anne Moreau
- Department of pathology; Centre Hospitalier Universitaire; Nantes France
| | - Nicolas Poirier
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Bernard Vanhove
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Fadi Fakhouri
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- Department of nephrology and immunology; Centre Hospitalier Universitaire; Nantes France
| |
Collapse
|
7
|
Lavainne F, Meffray E, Pepper RJ, Néel M, Delcroix C, Salama AD, Fakhouri F. Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. Nephrol Dial Transplant 2014; 29:1225-31. [DOI: 10.1093/ndt/gft517] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
8
|
Le Roux S, Pepper RJ, Dufay A, Néel M, Meffray E, Lamandé N, Rimbert M, Josien R, Hamidou M, Hourmant M, Cook HT, Charreau B, Larger E, Salama AD, Fakhouri F. Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2011; 23:155-64. [PMID: 22034638 DOI: 10.1681/asn.2010080858] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis exhibits endothelial damage, but the capacity for vessel repair in this disorder is not well understood. Here, we observed a marked increase in serum levels of soluble Flt1 (sFlt1), a potent inhibitor of vascular endothelial growth factor, in patients with active ANCA-associated vasculitis compared with patients during remission and other controls. Serum levels of sFlt1 correlated with C5a, an anaphylatoxin released after complement activation. Serum from patients with acute ANCA-associated vasculitis disrupted blood flow in the chicken chorioallantoic membrane assay, suggesting an antiangiogenic effect. Preincubation with excess human vascular endothelial growth factor prevented this effect. Anti-proteinase-3 (PR3) mAb and serum containing PR3-ANCA from patients with active vasculitis both induced a significant and sustained release of sFlt1 from monocytes, whereas anti-myeloperoxidase (MPO) mAb or polyclonal antibodies did not. However, the serum containing polyclonal PR3-ANCA did not induce release of sFlt1 from cultured human umbilical vein endothelial cells. In summary, these data suggest that anti-PR3 antibodies, and to a much lesser extent anti-MPO antibodies, increase sFlt1 during acute ANCA-associated vasculitis, leading to an antiangiogenic state that hinders endothelial repair.
Collapse
Affiliation(s)
- Sandrine Le Roux
- ITUN, U643, Department of Nephrology and Immunology, CHU de Nantes, 44000 Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Vercel C, Le Roux S, Pepper RA, Dufay A, Néel M, Lamandé N, Rimbert M, Hamidou M, Hourmant M, Cook HT, Salama A, Fakhouri F. Effet anti-angiogénique d’un excès de sFlt1 au cours des vascularites à ANCA. Nephrol Ther 2011. [DOI: 10.1016/j.nephro.2011.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
10
|
Le Roux S, Pepper R, Dufay A, Néel M, Lamandé N, Rimbert M, Josien R, Hamidou M, Hourmant M, Cook HT, Charreau B, Larger E, Salama A, Fakhouri F. Elevated soluble Flt1 mediates an anti-angiogenic state in patients with ANCA-associated vasculitis. Lab Invest 2010. [PMCID: PMC3007755 DOI: 10.1186/1479-5876-8-s1-p13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
|